Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Issued (2020 - 2024)

4D Molecular Therapeutics (FDMT) has disclosed Shares Issued for 5 consecutive years, with $300.9 million as the latest value for Q4 2024.

  • Quarterly Shares Issued rose 373.35% to $300.9 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $316.1 million through Dec 2024, up 1552.12% year-over-year, with the annual reading at $316.1 million for FY2024, 1552.12% up from the prior year.
  • Shares Issued for Q4 2024 was $300.9 million at 4D Molecular Therapeutics, up from -$19.6 million in the prior quarter.
  • The five-year high for Shares Issued was $300.9 million in Q4 2024, with the low at -$110.1 million in Q4 2023.
  • Average Shares Issued over 5 years is $50.3 million, with a median of $1.4 million recorded in 2023.
  • Peak annual rise in Shares Issued hit 2364.69% in 2024, while the deepest fall reached 338.57% in 2024.
  • Over 5 years, Shares Issued stood at $204.7 million in 2020, then tumbled by 44.16% to $114.3 million in 2021, then plummeted by 100.77% to -$875000.0 in 2022, then tumbled by 12479.66% to -$110.1 million in 2023, then soared by 373.35% to $300.9 million in 2024.
  • According to Business Quant data, Shares Issued over the past three periods came in at $300.9 million, -$19.6 million, and $34.9 million for Q4 2024, Q2 2024, and Q1 2024 respectively.